Bristol-Myers Squibb Company
Explore Bristol-Myers Squibb
Core profile pages, annual revenue records, and related research hubs for this company.
Bristol-Myers Squibb Company
Explore Bristol-Myers Squibb
Core profile pages, annual revenue records, and related research hubs for this company.
Company History
Founded 1989 in New York, New York
Squibb was founded in 1858 by Edward Robinson Squibb, a Navy pharmacist who was so disturbed by the quality of medicines supplied to military hospitals that he started manufacturing his own.
Edward Robinson Squibb was born in 1819 in New York, and after a distinguished career as a naval physician, he became frustrated by the impure and inconsistent quality of medical supplies used during the Mexican-American War and the early days of the Civil War. His decision to found his own pharmaceutical manufacturing company in Brooklyn, New York, in 1858 was driven by the explicit goal of applying rigorous scientific standards to the production of chemicals and medicines, ensuring that every batch met the highest possible purity standards. This focus on quality was not merely a moral imperative; it was a revolutionary business strategy that allowed the company to build brand trust, scale production, and establish a distribution network that would eventually span the globe. Squibb's shrewd business acumen and his willingness to invest heavily in proprietary manufacturing processes allowed the young company to carve out a niche in the growing market for patented, branded medicinal products, despite intense competition from established chemical manufacturers. His leadership laid the groundwork for the company's subsequent pivot to the industrial production of antibiotics during World War II, a move that would transform the company into a global biopharmaceutical powerhouse and generate the massive cash flows that funded its entry into the oncology and cardiovascular markets. Squibb's legacy is defined by his understanding that the future of healthcare lay in bringing scientific rigor and industrial efficiency to the business of human health, a philosophy that remains the bedrock of the organization's operations today.
Clinton F. Bristol was born in 1853 in Massachusetts, and after a brief career in the patent medicine industry, he recognized a critical flaw in the consumer health market of the late 19th century: the efficacy of over-the-counter medicines was entirely dependent on the inconsistent quality of their ingredients, a problem that plagued consumers and limited the scalability of treatments. His decision to co-found the Clinton Pharmaceutical Company in 1887 was driven by the explicit goal of applying industrial manufacturing principles to the production of proprietary medicines, ensuring that every batch contained a precise, standardized dose of the active compound. This focus on standardization was not merely a quality control measure; it was a revolutionary business strategy that allowed the company to build brand trust, scale production, and establish a distribution network that would eventually span the globe. Bristol's shrewd business acumen and his willingness to invest heavily in proprietary manufacturing processes allowed the young company to carve out a niche in the growing market for patented, branded medicinal products, despite intense competition from established chemical manufacturers. His leadership laid the groundwork for the company's subsequent pivot to the industrial production of antibiotics and other complex biologics in the mid-20th century, a move that would transform the company into a global biopharmaceutical powerhouse and generate the massive cash flows that funded its entry into the oncology and cardiovascular markets. Bristol's legacy is defined by his understanding that the future of healthcare lay in bringing scientific rigor and industrial efficiency to the business of human health, a philosophy that remains the bedrock of the organization's operations today.
Edward Robinson Squibb founded the company in Brooklyn, New York, with the explicit vision of producing chemicals and medicines of the highest possible purity, establishing the foundational business model of rigorous scientific quality control and industrial-scale pharmaceutical manufacturing.
Clinton F. Bristol and John K. Bristol co-founded the Clinton Pharmaceutical Company in Clinton, Massachusetts, with the vision of producing standardized, high-quality proprietary medicines, establishing the foundational business model of scalable, reliable consumer health manufacturing.
Squibb achieved the commercial-scale production of penicillin, followed by the rapid commercialization of other antibiotics, transforming the company from a modest chemical manufacturer into a global biopharmaceutical powerhouse and capturing a dominant market share in the anti-infective market.
Bristol-Myers and Squibb completed a $12.0 billion merger, combining the deep scientific expertise and oncology franchise of Squibb with the massive commercial infrastructure and consumer health portfolio of Bristol-Myers, creating a global biopharmaceutical entity with the scale and resources to compete with the largest players in the industry.
The FDA approved Yervoy (ipilimumab), the first immune checkpoint inhibitor to demonstrate a survival benefit in advanced melanoma, establishing the organization's leadership in the immuno-oncology market and generating billions of dollars in annual revenue.
The FDA approved Eliquis (apixaban) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, establishing the organization's leadership in the cardiovascular market and generating over $13.0 billion in annual revenue by FY2024.
The organization completed the $74.0 billion acquisition of Celgene, securing full ownership of the hematology franchise led by Revlimid and Pomalyst, and integrating Celgene's world-class immunology and inflammation research capabilities directly into its global R&D pipeline.
The organization deployed $33.0 billion to acquire Karuna Therapeutics ($14.0B), Mirati Therapeutics ($5.8B), and RayzeBio ($4.1B), securing exclusive rights to next-generation modalities in neuroscience (Cobenfy), targeted oncology (KRAS inhibitors), and radiopharmaceuticals, fundamentally transforming the portfolio.
The organization reported consolidated net revenues of $45.0 billion for FY2024, with the Pharmaceuticals division contributing the vast majority of this total through the sale of high-margin biologics, small molecules, and targeted therapies, while allocating approximately $10.5 billion to research and development.
The FDA approved Cobenfy (xanomeline and trospium chloride), the first muscarinic agonist for the treatment of schizophrenia in over 30 years, representing a major breakthrough in neuroscience and a potential blockbuster asset for the organization.
In 2025 Bristol Myers Squibb reported $48.194B in total revenues and $7.054B of net earnings attributable to BMS, while its Growth Portfolio rose 17%.
The organization completed the full acquisition of Celgene for $74.0 billion to secure full ownership of the hematology franchise led by Revlimid and Pomalyst, and to integrate Celgene's world-class immunology and inflammation research capabilities directly into its global R&D pipeline.
The organization acquired Karuna Therapeutics for $14.0 billion to secure exclusive rights to KarXT (Cobenfy), a novel muscarinic agonist for the treatment of schizophrenia, marking a decisive and aggressive entry into the highly lucrative neuroscience therapeutic area.
The organization acquired Mirati Therapeutics for $5.8 billion to secure exclusive rights to the KRAS inhibitor franchise, targeting the notoriously difficult-to-drug G12C and G12D mutations found in a significant percentage of non-small cell lung cancer, colorectal cancer, and pancreatic cancer cases.
The organization acquired RayzeBio for $4.1 billion to establish its leadership in the rapidly growing field of radiopharmaceutical therapies, securing a proprietary actinium-225 and yttrium-90 pipeline targeting somatostatin receptor-expressing neuroendocrine tumors and prostate-specific membrane antigen-expressing prostate cancers.
Bristol Myers Squibb is known for oncology, hematology, immunology, cardiovascular, neuroscience, cell therapy, and radiopharmaceutical medicines.
Bristol Myers Squibb reported $48.2B in FY2025 revenue.
Chris Boerner is the current CEO of Bristol Myers Squibb.
Bristol Myers Squibb has about 32,500 employees based on the latest annual reporting context.
The biggest risk is patent-cliff execution: generic pressure on legacy brands must be offset by launches such as Cobenfy, Opdivo Qvantig, Reblozyl, Breyanzi, and radiopharmaceutical programs.